Aldeyra Therapeutics IncNASDAQ:ALDX
- LAST PRICE3.4800
- TODAY'S CHANGE (%)0.0850 (2.5037%)
- Bid / Lots3.4800/ 15
- Ask / Lots3.5600/ 5
- Open / Previous Close3.4000 / 3.3950
- Day Range
- 52 Week Range
- Volume321,560
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | ALDX |
|---|---|---|
| 09:32 ET | 65110 | 3.4 |
| 09:34 ET | 700 | 3.4 |
| 09:36 ET | 500 | 3.405 |
| 09:41 ET | 653 | 3.45 |
| 09:43 ET | 650 | 3.45 |
| 09:45 ET | 1254 | 3.435 |
| 09:48 ET | 4511 | 3.45 |
| 09:54 ET | 500 | 3.45 |
| 09:57 ET | 498 | 3.44 |
| 09:59 ET | 700 | 3.45 |
| 10:01 ET | 100 | 3.45 |
| 10:03 ET | 100 | 3.46 |
| 10:06 ET | 1300 | 3.479 |
| 10:08 ET | 2266 | 3.48 |
| 10:15 ET | 2205 | 3.49 |
| 10:17 ET | 600 | 3.5 |
| 10:19 ET | 2144 | 3.545 |
| 10:21 ET | 1500 | 3.5399 |
| 10:24 ET | 100 | 3.5368 |
| 10:26 ET | 332 | 3.53 |
| 10:32 ET | 661 | 3.52 |
| 10:33 ET | 142 | 3.5101 |
| 10:46 ET | 12112 | 3.485 |
| 10:48 ET | 1300 | 3.49 |
| 10:50 ET | 220 | 3.49 |
| 11:02 ET | 600 | 3.47 |
| 11:04 ET | 389 | 3.4601 |
| 11:06 ET | 1000 | 3.47 |
| 11:08 ET | 500 | 3.47 |
| 11:09 ET | 313 | 3.47 |
| 11:11 ET | 279 | 3.47 |
| 11:18 ET | 100 | 3.47 |
| 11:26 ET | 200 | 3.475 |
| 11:27 ET | 3275 | 3.49 |
| 11:29 ET | 700 | 3.49 |
| 11:40 ET | 1107 | 3.48 |
| 11:45 ET | 900 | 3.4701 |
| 11:47 ET | 200 | 3.475 |
| 11:49 ET | 100 | 3.47 |
| 11:51 ET | 435 | 3.475 |
| 12:02 ET | 100 | 3.47 |
| 12:07 ET | 500 | 3.46 |
| 12:09 ET | 1204 | 3.46 |
| 12:20 ET | 241 | 3.46 |
| 12:21 ET | 200 | 3.46 |
| 12:23 ET | 1100 | 3.455 |
| 12:27 ET | 100 | 3.455 |
| 12:34 ET | 200 | 3.455 |
| 12:43 ET | 300 | 3.46 |
| 12:54 ET | 1000 | 3.4629 |
| 12:56 ET | 1900 | 3.4699 |
| 12:57 ET | 700 | 3.48 |
| 01:03 ET | 400 | 3.48 |
| 01:06 ET | 244 | 3.49 |
| 01:08 ET | 500 | 3.5 |
| 01:15 ET | 200 | 3.48 |
| 01:17 ET | 317 | 3.4897 |
| 01:19 ET | 200 | 3.48 |
| 01:33 ET | 100 | 3.47 |
| 01:42 ET | 300 | 3.47 |
| 01:44 ET | 100 | 3.475 |
| 01:50 ET | 100 | 3.475 |
| 01:51 ET | 100 | 3.475 |
| 01:53 ET | 430 | 3.48 |
| 02:00 ET | 1500 | 3.47 |
| 02:02 ET | 100 | 3.47 |
| 02:09 ET | 100 | 3.47 |
| 02:11 ET | 600 | 3.48 |
| 02:15 ET | 400 | 3.47 |
| 02:18 ET | 100 | 3.475 |
| 02:20 ET | 200 | 3.47 |
| 02:26 ET | 200 | 3.47 |
| 02:29 ET | 4660 | 3.47 |
| 02:31 ET | 2684 | 3.475 |
| 02:36 ET | 4779 | 3.47 |
| 02:38 ET | 1675 | 3.46 |
| 02:40 ET | 1100 | 3.455 |
| 02:42 ET | 500 | 3.455 |
| 02:45 ET | 200 | 3.455 |
| 02:47 ET | 600 | 3.455 |
| 02:49 ET | 100 | 3.455 |
| 02:51 ET | 1231 | 3.47 |
| 02:56 ET | 500 | 3.47 |
| 03:00 ET | 120 | 3.475 |
| 03:05 ET | 229 | 3.48 |
| 03:09 ET | 977 | 3.47 |
| 03:20 ET | 100 | 3.46 |
| 03:21 ET | 117 | 3.465 |
| 03:30 ET | 1135 | 3.475 |
| 03:32 ET | 215 | 3.47 |
| 03:34 ET | 400 | 3.475 |
| 03:36 ET | 400 | 3.47 |
| 03:38 ET | 300 | 3.47 |
| 03:39 ET | 5114 | 3.4666 |
| 03:41 ET | 907 | 3.47 |
| 03:43 ET | 300 | 3.47 |
| 03:45 ET | 205 | 3.465 |
| 03:48 ET | 100 | 3.465 |
| 03:50 ET | 1321 | 3.48 |
| 03:52 ET | 900 | 3.48 |
| 03:54 ET | 1235 | 3.485 |
| 03:56 ET | 500 | 3.48 |
| 03:57 ET | 1700 | 3.485 |
| 03:59 ET | 103669 | 3.48 |
Jun 20, 2024
Aldeyra Therapeutics Announces Advancement of New RASP Modulators and Recent Preclinical Data in Obesity at 2024 Investor Roundtable, from 7:00AM ET on Thursday Jun 20, 2024 by Dow Jones
7:00AM ET on Thursday Jun 20, 2024 by Dow Jones
Jun 13, 2024
Investigation Alert: Aldeyra, Eagle Pharmaceuticals, and Blue Ridge Bankshares: Johnson Fistel, LLP Encourages Long-Term Investors to Submit Their Information Below, from 11:02AM ET on Thursday Jun 13, 2024 by Dow Jones
11:02AM ET on Thursday Jun 13, 2024 by Dow JonesAldeyra Therapeutics Completes Enrollment in Phase 3 Clinical Trial of Reproxalap in Dry Eye Disease, from 7:00AM ET on Thursday Jun 13, 2024 by Dow Jones
7:00AM ET on Thursday Jun 13, 2024 by Dow Jones
Jun 12, 2024
Aldeyra Therapeutics to Host Investor Roundtable Q&A, from 7:00AM ET on Wednesday Jun 12, 2024 by Dow Jones
7:00AM ET on Wednesday Jun 12, 2024 by Dow Jones
May 29, 2024
Aldeyra Therapeutics to Participate in the Jefferies Global Healthcare Conference, from 7:00AM ET on Wednesday May 29, 2024 by Dow Jones
7:00AM ET on Wednesday May 29, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Aldeyra Therapeutics Inc | 206.8M | -6.9x | --- |
Rani Therapeutics Holdings Inc | 209.2M | -3.2x | --- |
Acrivon Therapeutics Inc | 204.1M | -2.3x | --- |
Greenwich Lifesciences Inc | 209.6M | -22.6x | --- |
Prelude Therapeutics Inc | 209.8M | -2.0x | --- |
Rezolute Inc | 203.0M | -3.5x | --- |
Company Information
Aldeyra Therapeutics, Inc. is a biotechnology company, which is engaged in discovering therapies designed to treat immune-mediated diseases. The Company's product candidates include reactive aldehyde species (RASP) modulators ADX-629, ADX-246, ADX-248, and chemically related molecules for the treatment of systemic and retinal immune-mediated diseases. Its pre-commercial product candidates are reproxalap, a RASP modulator for the potential treatment of dry eye disease and allergic conjunctivitis, and ADX-2191, a novel formulation of intravitreal methotrexate for the treatment of proliferative vitreoretinopathy and retinitis pigmentosa. Its ADX-629, is an orally administered RASP modulator in clinical development for atopic dermatitis, idiopathic nephrotic syndrome, moderate alcohol-associated hepatitis, chronic cough, and Sjogren-Larsson Syndrome. Its preclinical RASP platform includes ADX-246 and ADX-248 in development for metabolic, retinal diseases and systemic inflammatory diseases.
Contact Information
- Headquarters
- 131 HARTWELL AVENUE, SUITE 320LEXINGTON, MA, United States 02421
- Phone
- 781-761-4904
- Fax
- 302-636-5454
Executives
- Independent Chairman of the Board
- Richard Douglas
- President, Chief Executive Officer, Director
- Todd Brady
- Senior Vice President - Finance, Interim Chief Financial Officer
- Bruce Greenberg
- Chief Development Officer
- Stephen Machatha
- Independent Director
- Ben Bronstein
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $206.8M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 59.4M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.45 |
EPS | $-0.51 |
Book Value | $2.02 |
P/E Ratio | -6.9x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
